Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice (original) (raw)
- Article
- Published: 01 August 1995
- Charles A. Omer1,
- Michael W. Conner2,
- Neville J. Anthony3,
- Joseph P. Davide1,
- S. Jane Desolms3,
- Elizabeth A. Giuliani3,
- Robert P. Gomez3,
- Samuel L. Graham3,
- Kelly Hamilton1,
- Laurence K. Handt4,
- George D. Hartman3,
- Kenneth S. Koblan1,
- Astrid M. Kral1,
- Patricia J. Miller1,
- Scott D. Mosser1,
- Timothy J. O'Neill1,
- Elaine Rands1,
- Michael D. Schaber1,
- Jackson B. Gibbs1 &
- …
- Allen Oliff1
Nature Medicine volume 1, pages 792–797 (1995)Cite this article
- 991 Accesses
- 9 Altmetric
- Metrics details
Abstract
For Ras oncoproteins to transform mammalian cells, they must be post-translationally modified with a farnesyl group in a reaction catalysed by the enzyme farnesyl-protein transferase (FPTase). Inhibitors of FPTase have therefore been proposed as anti-cancer agents. We show that L-744,832, which mimics the CaaX motif to which the farnesyl group is added, is a potent and selective inhibitor of FPTase. In MMTV-_v_-Ha-ras mice bearing palpable tumours, daily administration of L-744,832 caused tumour regression. Following cessation of treatment, tumours reappeared, the majority of which regressed upon retreatment. No systemic toxicity was found upon necropsy of L-744,832-treated mice. This first demonstration of anti-FPTase-mediated tumour regression suggests that FPTase inhibitors may be safe and effective anti-tumour agents in some cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
References
- Barbacid, M. Ras genes. Annu. Rev. Biochem. 56, 779–827 (1987).
Article CAS Google Scholar - Lowy, D.R. & Willumsen, B.M. Function and regulation of ras . Annu. Rev. Biochem. 62, 851–891 (1993).
Article CAS Google Scholar - Adams, J.M. & Cory, S. Transgenic models of tumor development. Science 254, 1161–1167 (1991).
Article CAS Google Scholar - Clark, G.J. & Der, C.J. Ras proto-oncogene activation in human malignancy. in Cellular Cancer Markers (eds Garrett, C.T. & Sell, S.) 17–52 (Humana Press, Totowa, New Jersey, 1995).
Chapter Google Scholar - Bos, J.L. Ras oncogenes in human cancer: A review. Cancer Res. 49, 4682–4689 (1989).
CAS PubMed Google Scholar - Gibbs, J.B., C-terminal processing enzymes—new drug targets? Cell 65, 1–4 (1991).
Article CAS Google Scholar - Clarke, S. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu. Rev. Biochem. 61, 355–386 (1992).
Article CAS Google Scholar - Gibbs, J.B., Oliff, A. & Kohl, N.E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77, 175–178 (1994).
Article CAS Google Scholar - Patel, D.V. et al. Phosphinyl acid-based bisubstrate analog inhibitors of Ras farnesyl protein transferase. J. med. Chem. 38, 435–442 (1995).
Article CAS Google Scholar - Kohl, N.E. et al. Farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. natn. Acad. Sci. U.S.A. 91, 9141–9145 (1994).
Article CAS Google Scholar - Sinn, E. et al. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49, 465–475 (1987).
Article CAS Google Scholar - Dexter, D.L., Diamond, M., Creveling, J. & Chen, S.-F. Chemotherapy of mammary carcinomas arising in ras transgenic mice. Invest, new Drugs 11, 161–168 (1993).
Article CAS Google Scholar - James, G.L. et al. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells. Science 260, 1937–1942 (1993).
Article CAS Google Scholar - Prendergast, G.C. et al. Farnesyltransferase inhibition causes morphological reversion of Ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Molec. cell. Biol. 14, 4193–4202 (1994).
Article CAS Google Scholar - James, G.L., Goldstein, J.L., Pathak, R.K., Anderson, R.G.W. & Brown, M.S. A prenylated protein of peroxisomes. J. biol. Chem. 269, 14182–14190 (1994).
CAS PubMed Google Scholar - Vogelstein, B. & Kinzler, K.W. The multistep nature of cancer. Trends Genet. 9, 138–141 (1993).
Article CAS Google Scholar - Yamada, H., Yoshida, T., Sakamoto, H., Terada, M. & Sugimura, T. Establishment of a human pancreatic adenocarcinoma cell line (PSN-1) with amplification of both c-myc and activated c-Ki-ras by a point mutation. Biochem. biophys. Res. Commun. 140, 167–173 (1986).
Article CAS Google Scholar
Author information
Authors and Affiliations
- Department of Cancer Research, Merck Research Laboratories, West Point, Pennsylvania, 19486, USA
Nancy E. Kohl, Charles A. Omer, Joseph P. Davide, Kelly Hamilton, Kenneth S. Koblan, Astrid M. Kral, Patricia J. Miller, Scott D. Mosser, Timothy J. O'Neill, Elaine Rands, Michael D. Schaber, Jackson B. Gibbs & Allen Oliff - Department of Safety Assessment, Merck Research Laboratories, West Point, Pennsylvania, 19486, USA
Michael W. Conner - Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania, 19486, USA
Neville J. Anthony, S. Jane Desolms, Elizabeth A. Giuliani, Robert P. Gomez, Samuel L. Graham & George D. Hartman - Laboratory Animal Resources, Merck Research Laboratories, West Point, Pennsylvania, 19486, USA
Laurence K. Handt
Authors
- Nancy E. Kohl
You can also search for this author inPubMed Google Scholar - Charles A. Omer
You can also search for this author inPubMed Google Scholar - Michael W. Conner
You can also search for this author inPubMed Google Scholar - Neville J. Anthony
You can also search for this author inPubMed Google Scholar - Joseph P. Davide
You can also search for this author inPubMed Google Scholar - S. Jane Desolms
You can also search for this author inPubMed Google Scholar - Elizabeth A. Giuliani
You can also search for this author inPubMed Google Scholar - Robert P. Gomez
You can also search for this author inPubMed Google Scholar - Samuel L. Graham
You can also search for this author inPubMed Google Scholar - Kelly Hamilton
You can also search for this author inPubMed Google Scholar - Laurence K. Handt
You can also search for this author inPubMed Google Scholar - George D. Hartman
You can also search for this author inPubMed Google Scholar - Kenneth S. Koblan
You can also search for this author inPubMed Google Scholar - Astrid M. Kral
You can also search for this author inPubMed Google Scholar - Patricia J. Miller
You can also search for this author inPubMed Google Scholar - Scott D. Mosser
You can also search for this author inPubMed Google Scholar - Timothy J. O'Neill
You can also search for this author inPubMed Google Scholar - Elaine Rands
You can also search for this author inPubMed Google Scholar - Michael D. Schaber
You can also search for this author inPubMed Google Scholar - Jackson B. Gibbs
You can also search for this author inPubMed Google Scholar - Allen Oliff
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Kohl, N., Omer, C., Conner, M. et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice.Nat Med 1, 792–797 (1995). https://doi.org/10.1038/nm0895-792
- Received: 25 April 1995
- Accepted: 07 June 1995
- Issue Date: 01 August 1995
- DOI: https://doi.org/10.1038/nm0895-792